Omicron - Decoupling Infection from Severe Disease.
作者信息
Moore Penny L, Baden Lindsey R
机构信息
From the Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, and the South African Medical Research Council Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, and the Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban - all in South Africa (P.L.M.).
出版信息
N Engl J Med. 2022 Apr 7;386(14):1361-1362. doi: 10.1056/NEJMe2201812.
Abstract
摘要
相似文献
1
Omicron - Decoupling Infection from Severe Disease.奥密克戎——将感染与重症脱钩。
N Engl J Med. 2022 Apr 7;386(14):1361-1362. doi: 10.1056/NEJMe2201812.
2
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间，加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局，期间 B.1.617.2（德尔塔）和 B.1.1.529（奥密克戎）变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
3
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
4
SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.SARS-CoV-2 B.1.1.529（奥密克戎）变异株-美国，2021 年 12 月 1 日-8 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734. doi: 10.15585/mmwr.mm7050e1.
5
Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.奥密克戎 SARS-CoV-2 新变体：全球流行情况以及生物学和临床特征。
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018. doi: 10.26355/eurrev_202112_27652.
6
The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.假型 SARS-CoV-2 变异株奥密克戎的显著免疫逃逸。
Emerg Microbes Infect. 2022 Dec;11(1):1-5. doi: 10.1080/22221751.2021.2017757.
7
[Analyze the clinical characteristics of mild and severe SARS-CoV-2 infected patients based on the local Omicron variant epidemic].基于本地奥密克戎变异株流行情况分析新型冠状病毒感染轻症和重症患者的临床特征
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Jan;35(1):32-36. doi: 10.3760/cma.j.cn121430-20220406-00339.
8
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?奥密克戎：为何最新的 SARS-CoV-2 变体如此令人担忧？
J Virol. 2022 Mar 23;96(6):e0207721. doi: 10.1128/jvi.02077-21.
9
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性：一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
10
Acute severe hepatitis as a presenting symptom in clinically stable patients admitted with SARS-CoV-2 Omicron infection.以奥密克戎感染住院的临床稳定患者为首发症状的急性重症肝炎。
Hepatol Commun. 2023 Mar 30;7(4). doi: 10.1097/HC9.0000000000000115. eCollection 2023 Apr 1.
引用本文的文献
1
Clinical characteristics and risk factors for a prolonged length of stay of patients with asymptomatic and mild COVID-19 during the wave of Omicron from Shanghai, China.中国上海奥密克戎变异株流行期间无症状和轻症 COVID-19 患者住院时间延长的临床特征和危险因素。
BMC Infect Dis. 2022 Dec 16;22(1):947. doi: 10.1186/s12879-022-07935-w.
2
Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV).适体门控介孔硅纳米颗粒用于 N 蛋白触发的瑞德西韦释放和新型冠状病毒（2019-nCoV）治疗。
Biosensors (Basel). 2022 Nov 1;12(11):950. doi: 10.3390/bios12110950.
3
Nasal irrigation efficiently attenuates SARS-CoV-2 Omicron infection, transmission and lung injury in the Syrian hamster model.鼻腔冲洗可有效减轻叙利亚仓鼠模型中SARS-CoV-2奥密克戎毒株的感染、传播和肺部损伤。
iScience. 2022 Dec 22;25(12):105475. doi: 10.1016/j.isci.2022.105475. Epub 2022 Nov 2.
4
Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.SARS-CoV-2 奥密克戎变异株 BA.1 和 BA.2 中刺突感染力、加工和中和的决定因素。
Cell Host Microbe. 2022 Sep 14;30(9):1255-1268.e5. doi: 10.1016/j.chom.2022.07.006. Epub 2022 Jul 18.
本文引用的文献
1
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.Ad26.COV2.S 突破性感染可诱导针对奥密克戎和其他关切的 SARS-CoV-2 变体的高滴度中和抗体。
Cell Rep Med. 2022 Feb 10;3(3):100535. doi: 10.1016/j.xcrm.2022.100535. eCollection 2022 Mar 15.
2
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.南非奥密克戎变异株下的人群免疫力与新冠病毒疾病严重程度。
N Engl J Med. 2022 Apr 7;386(14):1314-1326. doi: 10.1056/NEJMoa2119658. Epub 2022 Feb 23.
3
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）突破性感染引发强效、广泛且持久的中和抗体反应。
Cell. 2022 Mar 3;185(5):872-880.e3. doi: 10.1016/j.cell.2022.01.011. Epub 2022 Jan 20.
4
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.新冠病毒奥密克戎改变 TMPRSS2 的使用方式影响其感染性和融合性。
Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022 Feb 1.
5
T cell responses to SARS-CoV-2 spike cross-recognize Omicron.T 细胞对 SARS-CoV-2 刺突蛋白的交叉识别可识别奥密克戎。
Nature. 2022 Mar;603(7901):488-492. doi: 10.1038/s41586-022-04460-3. Epub 2022 Jan 31.
6
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.南非对 SARS-CoV-2 奥密克戎变异株临床严重程度的早期评估：一项数据关联研究。
Lancet. 2022 Jan 29;399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4. Epub 2022 Jan 19.
7
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.南非 SARS-CoV-2 奥密克戎变异株的快速流行扩张。
Nature. 2022 Mar;603(7902):679-686. doi: 10.1038/s41586-022-04411-y. Epub 2022 Jan 7.
8
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.奥密克戎能广泛但不完全地逃避辉瑞 BNT162b2 的中和作用。
Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23.
9
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
10
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.先前感染 SARS-CoV-2 以依赖于变异体的方式增强和拓宽了 Ad26.COV2.S 的免疫原性。
Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5. doi: 10.1016/j.chom.2021.10.003. Epub 2021 Oct 13.
Zotero 插件